List view / Grid view
26 January 2016 | By Victoria White
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in immuno-oncology...
26 January 2016 | By Victoria White
During trials of ABTL0812, researchers identified a new mechanism of action: the activation of the PPAR receptors and the TRIB3 gene, leading to inhibition of the Akt/mTOR pathway...
25 January 2016 | By Victoria White
The Zika virus is responsible for an unprecedented epidemic currently sweeping through the tropical regions of the Americas...
25 January 2016 | By Victoria White
The Apollo Therapeutics Fund will support the translation of ground-breaking academic science into innovative new medicines for a broad range of diseases...
25 January 2016 | By Victoria White
The alliance will give clients access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s approach to hit identification and drug design...
22 January 2016 | By Victoria White
Researchers used a high-efficiency method they developed to quickly isolate and generate large quantities of monoclonal human antibodies from the blood of survivors of a 2007 outbreak in Uganda who were infected by the Bundibugyo Ebola virus...
22 January 2016 | By Victoria White
The research from Georgia State University scientists provides strong translational potential with respect to biomarkers that play critical roles in the development of endometrial/lung tumours...
22 January 2016 | By Victoria White
Dartmouth researchers have discovered that one of their recently discovered chemical reactions is capable of delivering some of the most potent and rare neurotrophins...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells...
21 January 2016 | By Victoria White
MRCT will identify projects with the greatest promise for advancement as investigational therapies and advise the Alzheimer's Association on strategies for moving them forward such that they realise the maximum potential...
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
21 January 2016 | By Victoria White
The researchers have announced a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60% when replacing a short stretch of DNA with another...
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
